Adiponectin Reduces Plasma Triglyceride by Increasing VLDL Triglyceride Catabolism

  1. Liping Qiao1,
  2. Chenhui Zou1,
  3. Deneys R. van der Westhuyzen12 and
  4. Jianhua Shao1
  1. 1Graduate Center for Nutritional Sciences, University of Kentucky, Lexington, Kentucky
  2. 2Department of Internal Medicine and Cardiovascular Research Center, University of Kentucky, Lexington, Kentucky
  1. Corresponding author: Jianhua Shao, jianhuashao{at}uky.edu

Abstract

OBJECTIVE—Adiponectin is an adipocyte-derived hormone that plays an important role in glucose and lipid metabolism. The main aims of this study are to investigate the effects of adiponectin on VLDL triglyceride (VLDL-TG) metabolism and the underlying mechanism.

RESEARCH DESIGN AND METHODS—Adenoviruses were used to generate a mouse model with elevated circulating adiponectin. HepG2 and C2C12 cells were treated with recombinant human adiponectin.

RESULTS—Three days after Ad-mACRP30 adenovirus injection, plasma adiponectin protein levels were increased 12-fold. All three main multimeric adiponectin molecules were proportionally elevated. Fasting plasma TG levels were significantly decreased (∼40%) in the mice with elevated adiponectin in circulation, as were the plasma levels of large and medium VLDL subclasses. Although apolipoprotein B mRNA levels were robustly suppressed in the livers of adiponectin-overexpressing mice and in cultured HepG2 cells treated with recombinant human adiponectin, hepatic VLDL-TG secretion rates were not altered by elevated plasma adiponectin. However, Ad-mACRP30–treated mice exhibited a significant increase of postheparin plasma lipoprotein lipase (LPL) activity compared with mice that received control viral vector. Skeletal muscle LPL activity and mRNA levels of LPL and VLDL receptor (VLDLr) were also increased in Ad-mACRP30–treated mice. Recombinant human adiponectin treatment increased LPL and VLDLr mRNA levels in differentiated C1C12 myotubes.

CONCLUSIONS—These results suggest that adiponectin decreases plasma TG levels by increasing skeletal muscle LPL and VLDLr expression and consequently VLDL-TG catabolism.

Footnotes

  • Published ahead of print at http://diabetes.diabetesjournals.org on 28 March 2008.

    Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

    The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted March 24, 2008.
    • Received March 29, 2007.
| Table of Contents

This Article

  1. Diabetes vol. 57 no. 7 1824-1833
  1. Online-Only Appendix
  2. All Versions of this Article:
    1. db07-0435v1
    2. db07-0435v2
    3. db07-0435v3
    4. 57/7/1824 most recent